Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
NCT00094978 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2019-12-12 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HDAC1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-10-26Results posted on the registry: Merck Sharp & Dohme LLC, Vorinostat + Placebo (NCT00128102)
- 2020-10-19Also stopped (terminated): Herlev Hospital, Belinostat and Erlotinib (NCT01188707)
- 2020-07-29Also stopped (terminated): AIDS Malignancy Consortium, vorinostat + carboplatin (NCT01249443)
- 2019-10-04Also stopped (withdrawn): Muhammad Furqan, PDR001 + Panobinostat (NCT03982134)
- 2019-05-09Results posted on the registry: National Cancer Institute (NCI), Azacitidine 30mg/m2 + Entinostat (NCT00387465)
- 2019-02-05Results posted on the registry: National Cancer Institute (NCI), Azacitidine + Entinostat (NCT01207726)
- 2019-02-05Also stopped (terminated): National Cancer Institute (NCI), Azacitidine + Entinostat (NCT01207726)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision